Anti-programmed cell death-1 (PD-1) protein monoclonal antibodies nivolumab and pembrolizumab are approved for the treatment of patients with recurrent or metastatic head and neck cancers (R/M HNC) [1]. Here, PDCD1 is linked to head and neck cancer.